| Prodrugs: design and clinical applications J Rautio, H Kumpulainen, T Heimbach, R Oliyai, D Oh, T Järvinen, ... Nature reviews Drug discovery 7 (3), 255-270, 2008 | 1992 | 2008 |
| Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective HM Jones, Y Chen, C Gibson, T Heimbach, N Parrott, SA Peters, ... Clinical Pharmacology & Therapeutics 97 (3), 247-262, 2015 | 460 | 2015 |
| Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs T Heimbach, DM Oh, LY Li, N Rodrı́guez-Hornedo, G Garcia, D Fleisher International journal of pharmaceutics 261 (1-2), 81-92, 2003 | 100 | 2003 |
| Absorption rate limit considerations for oral phosphate prodrugs T Heimbach, DM Oh, LY Li, M Forsberg, J Savolainen, J Leppänen, ... Pharmaceutical research 20, 848-856, 2003 | 97 | 2003 |
| Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor YS Cho, JR Levell, G Liu, T Caferro, J Sutton, CM Shafer, A Costales, ... ACS medicinal chemistry letters 8 (10), 1116-1121, 2017 | 96 | 2017 |
| Novel Orally Swallowable IntelliCap® Device to Quantify Regional Drug Absorption in Human GI Tract Using Diltiazem as Model Drug D Becker, J Zhang, T Heimbach, RC Penland, C Wanke, J Shimizu, ... AAPS PharmSciTech 15, 1490-1497, 2014 | 96 | 2014 |
| Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link—a Workshop Summary Report T Heimbach, S Suarez-Sharp, M Kakhi, N Holmstock, A Olivares-Morales, ... The AAPS Journal 21, 1-15, 2019 | 77 | 2019 |
| Overcoming poor aqueous solubility of drugs for oral delivery T Heimbach, D Fleisher, A Kaddoumi Prodrugs: Challenges and Rewards Part 1, 157-215, 2007 | 77 | 2007 |
| Physiologically‐based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective T Heimbach, Y Chen, J Chen, V Dixit, N Parrott, SA Peters, I Poggesi, ... Clinical Pharmacology & Therapeutics 110 (2), 297-310, 2021 | 72 | 2021 |
| A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy B Xia, T Heimbach, R Gollen, C Nanavati, H He The AAPS journal 15, 1012-1024, 2013 | 71 | 2013 |
| Use of physiologically based pharmacokinetic (PBPK) modeling for predicting drug-food interactions: an industry perspective AE Riedmaier, K DeMent, J Huckle, P Bransford, C Stillhart, R Lloyd, ... The AAPS journal 22, 1-15, 2020 | 70 | 2020 |
| Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data T Heimbach, B Xia, T Lin, H He The AAPS journal 15, 143-158, 2013 | 65 | 2013 |
| Food effect projections via physiologically based pharmacokinetic modeling: predictive case studies C Tistaert, T Heimbach, B Xia, N Parrott, TS Samant, F Kesisoglou Journal of pharmaceutical sciences 108 (1), 592-602, 2019 | 64 | 2019 |
| Applications of clinically relevant dissolution testing: workshop summary report S Suarez-Sharp, M Cohen, F Kesisoglou, A Abend, P Marroum, ... The AAPS Journal 20, 1-14, 2018 | 64 | 2018 |
| IMI–Oral biopharmaceutics tools project–Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results A Margolskee, AS Darwich, X Pepin, L Aarons, A Galetin, ... European Journal of Pharmaceutical Sciences 96, 610-625, 2017 | 64 | 2017 |
| Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat LY Li, GL Amidon, JS Kim, T Heimbach, F Kesisoglou, JT Topliss, ... Journal of Pharmacology and Experimental Therapeutics 301 (2), 586-593, 2002 | 60 | 2002 |
| Design and synthesis of novel quinoxaline-2, 3-dione AMPA/GlyN receptor antagonists: amino acid derivatives SS Nikam, JJ Cordon, DF Ortwine, TH Heimbach, AC Blackburn, ... Journal of medicinal chemistry 42 (12), 2266-2271, 1999 | 59 | 1999 |
| Physiologically based absorption modeling to impact biopharmaceutics and formulation strategies in drug development—industry case studies F Kesisoglou, J Chung, J van Asperen, T Heimbach Journal of pharmaceutical sciences 105 (9), 2723-2734, 2016 | 54 | 2016 |
| Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory, industrial and academic perspective W Lin, Y Chen, JD Unadkat, X Zhang, D Wu, T Heimbach Pharmaceutical Research 39 (8), 1701-1731, 2022 | 53 | 2022 |
| Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor X Tian, H Zhang, T Heimbach, H He, A Buchbinder, M Aghoghovbia, ... The Journal of Clinical Pharmacology 58 (12), 1533-1540, 2018 | 52 | 2018 |
